2/18
04:17 pm
rvmd
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026 [Yahoo! Finance]
Low
Report
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026 [Yahoo! Finance]
2/18
04:05 pm
rvmd
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026
Low
Report
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026
2/17
08:42 am
rvmd
Revolution Medicines (NASDAQ:RVMD) had its "overweight" rating reaffirmed by analysts at Benchmark Co..
Medium
Report
Revolution Medicines (NASDAQ:RVMD) had its "overweight" rating reaffirmed by analysts at Benchmark Co..
2/11
11:03 am
rvmd
Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript [Seeking Alpha]
Medium
Report
Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript [Seeking Alpha]
2/4
04:05 pm
rvmd
Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Low
Report
Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026
2/3
12:51 pm
rvmd
MSD's 2026 sales forecast falls short amid patent losses despite strong Q4 [Yahoo! Finance]
Low
Report
MSD's 2026 sales forecast falls short amid patent losses despite strong Q4 [Yahoo! Finance]
2/2
01:32 pm
rvmd
Revolution Medicines (NASDAQ:RVMD) had its price target raised by analysts at JPMorgan Chase & Co. from $92.00 to $122.00. They now have an "overweight" rating on the stock.
Low
Report
Revolution Medicines (NASDAQ:RVMD) had its price target raised by analysts at JPMorgan Chase & Co. from $92.00 to $122.00. They now have an "overweight" rating on the stock.
1/29
08:00 am
rvmd
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
Low
Report
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
1/28
07:02 pm
rvmd
Merck Ends Revolution Medicines Talks As Oncology Plans And Valuation Weighed [Yahoo! Finance]
Low
Report
Merck Ends Revolution Medicines Talks As Oncology Plans And Valuation Weighed [Yahoo! Finance]
1/27
08:08 am
rvmd
Revolution Medicines (NASDAQ:RVMD) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Low
Report
Revolution Medicines (NASDAQ:RVMD) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
1/27
05:31 am
rvmd
Tubulis Adds Steve Kelsey as Independent Director to its Advisory Board [Yahoo! Finance]
Low
Report
Tubulis Adds Steve Kelsey as Independent Director to its Advisory Board [Yahoo! Finance]
1/27
05:17 am
rvmd
Revolution Medicines (RVMD) Dives 16.9% as Merck Withdraws Takeover Plan [Yahoo! Finance]
Low
Report
Revolution Medicines (RVMD) Dives 16.9% as Merck Withdraws Takeover Plan [Yahoo! Finance]
1/26
12:38 pm
rvmd
Merck Walks Away: What The Failed Acquisition Means For Revolution Medicines [Seeking Alpha]
Low
Report
Merck Walks Away: What The Failed Acquisition Means For Revolution Medicines [Seeking Alpha]
1/26
07:36 am
rvmd
S&P 500 Futures Decline in Premarket Trading; Revolution Medicines, UFP Industries Lag [Barron's]
Medium
Report
S&P 500 Futures Decline in Premarket Trading; Revolution Medicines, UFP Industries Lag [Barron's]
1/25
08:33 pm
rvmd
Is It Too Late To Consider Revolution Medicines (RVMD) After Its 187% One-Year Surge? [Yahoo! Finance]
High
Report
Is It Too Late To Consider Revolution Medicines (RVMD) After Its 187% One-Year Surge? [Yahoo! Finance]
1/25
03:43 pm
rvmd
Merck no longer in talks to buy Revolution Medicines, WSJ reports [Yahoo! Finance]
High
Report
Merck no longer in talks to buy Revolution Medicines, WSJ reports [Yahoo! Finance]
1/25
02:59 pm
rvmd
Merck is said to halt acquisition talks with cancer drug developer Revolution [Seeking Alpha]
High
Report
Merck is said to halt acquisition talks with cancer drug developer Revolution [Seeking Alpha]
1/23
04:48 pm
rvmd
Jim Cramer Highlights “Takeover Interest” in Revolution Medicines [Yahoo! Finance]
High
Report
Jim Cramer Highlights “Takeover Interest” in Revolution Medicines [Yahoo! Finance]
1/22
10:02 am
rvmd
Revolution Medicines (NASDAQ:RVMD) was given a new $170.00 price target on by analysts at UBS Group AG.
Low
Report
Revolution Medicines (NASDAQ:RVMD) was given a new $170.00 price target on by analysts at UBS Group AG.
1/22
09:04 am
rvmd
Revolution Medicines (NASDAQ:RVMD) had its price target raised by analysts at Stifel Nicolaus from $85.00 to $170.00. They now have a "buy" rating on the stock.
Low
Report
Revolution Medicines (NASDAQ:RVMD) had its price target raised by analysts at Stifel Nicolaus from $85.00 to $170.00. They now have a "buy" rating on the stock.
1/21
07:17 am
rvmd
Revolution Medicines (NASDAQ:RVMD) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
Revolution Medicines (NASDAQ:RVMD) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
1/20
08:11 am
rvmd
Revolution Medicines (NASDAQ:RVMD) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Revolution Medicines (NASDAQ:RVMD) had its "buy" rating reaffirmed by analysts at Guggenheim.
1/19
07:40 pm
rvmd
Janus Henderson Enterprise Fund Q4 2025 Portfolio Review [Seeking Alpha]
Low
Report
Janus Henderson Enterprise Fund Q4 2025 Portfolio Review [Seeking Alpha]
1/19
07:26 pm
rvmd
Janus Henderson Enterprise Fund Q4 2025 Commentary [Seeking Alpha]
Medium
Report
Janus Henderson Enterprise Fund Q4 2025 Commentary [Seeking Alpha]
1/16
06:50 am
rvmd
On biotech's biggest stage, renewed excitement gets a stress test [Yahoo! Finance]
Low
Report
On biotech's biggest stage, renewed excitement gets a stress test [Yahoo! Finance]